

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau**B5**

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 47/48	A1	(11) International Publication Number: WO 98/48840 (43) International Publication Date: 5 November 1998 (05.11.98)
(21) International Application Number: PCT/US98/07634 (22) International Filing Date: 28 April 1998 (28.04.98) (30) Priority Data: 08/839,101 29 April 1997 (29.04.97) US (71) Applicant: SCHERING CORPORATION [US/US]; 2000 Galloping Hill Road, Kenilworth, NJ 07033-0530 (US). (72) Inventors: GLUE, Paul; 13 Allens Corner Road, Flemington, NJ 08822 (US). CUTLER, David, L.; 4 Windsor Way, Morristown, NJ 07960 (US). AFFRIME, Melton, B.; 2 Horseshoe Drive, Flemington, NJ 08822 (US). (74) Agents: McLAUGHLIN, Jaye, P. et al.; Schering-Plough Corporation, Patent Dept., K-6-1 1990, 2000 Galloping Hill Road, Kenilworth, NJ 07033-0530 (US).		(81) Designated States: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CZ, EE, GE, GW, HU, ID, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UZ, VN, YU, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>
(54) Title: POLYETHYLENE GLYCOL-INTERFERON ALPHA CONJUGATES FOR THERAPY OF INFECTION (57) Abstract A method comprising administering a PEG ₁₂₀₀₀ -IFN alpha conjugate to an individual afflicted with a viral infection susceptible of treatment with interferon alpha, preferably chronic hepatitis C, is disclosed.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

5

POLYETHYLENE GLYCOL-INTERFERON ALPHA CONJUGATES FOR THERAPY OF INFECTION

Cross-reference to Related Applications

10 This PCT application claims priority from United States application
Serial No. 08/839,101, filed April 29, 1997, which is a continuation-in-part of
application Serial No. 08/742,305, filed November 1, 1996, which is a
continuation of provisional application Serial No. 60/006,130, filed November
2, 1995, the disclosures of which are hereby incorporated in their entireties by
15 reference.

Background Of The Invention

 The present invention relates to a method of treating viral
infections, in particular, viral infections that are susceptible to treatment with
20 interferon alpha, comprising the administration of an amount of a polyethylene
glycol-interferon alpha conjugate, which amount is effective to treat the viral
infection while reducing or eliminating adverse side effects normally associated
with administration of interferon alpha. In a preferred embodiment of the
invention, administration of a polyethylene glycol having an average molecular
25 weight of 12,000 conjugated to interferon alpha is used to treat chronic hepatitis
C.

 Interferons are a family of naturally occurring small proteins and
glycoproteins produced and secreted by most nucleated cells in response to
viral infection as well as other antigenic stimuli. Interferons render cells

resistant to viral infection and exhibit a wide variety of actions on cells. They exert their cellular activities by binding to specific membrane receptors on the cell surface. Once bound to the cell membrane, interferons initiate a complex sequence of intracellular events. *In vitro* studies demonstrated that these
5 include the induction of certain enzymes, suppression of cell proliferation, immunomodulating activities such as enhancement of the phagocytic activity of macrophages and augmentation of the specific cytotoxicity of lymphocytes for target cells, and inhibition of virus replication in virus-infected cells.

Nonimmune interferons, which include both alpha and beta
10 interferons, are known to suppress human immunodeficiency virus (HIV) in both acutely and chronically infected cells. Poli and Fauci, 1992, *AIDS Research and Human Retroviruses* 8(2):191-197. Interferons, in particular, alpha interferons, have received considerable attention as therapeutic agents in the treatment of hepatitis C virus (HCV)-related disease due to their antiviral activity.
15 Hoofnagle *et al.*, in: *Viral Hepatitis 1981 International Symposium*, 1982, Philadelphia, Franklin Institute Press; Hoofnagle *et al.*, 1986, *New Eng. J. Med.* 315:1575-1578; Thomson, 1987, *Lancet* 1:539-541 Kiyosawa *et al.*, 1983, in: Zuckerman, ed., *Viral Hepatitis and Liver Disease*, Allen K. Liss, New York pp. 895-897; Hoofnagle *et al.*, 1985, *Sem. Liv. Dis.*, 1985, 9:259-263.

20 Chronic hepatitis C is an insidious and slowly progressive disease having a significant impact on the quality of life. Despite improvement in the quality of the blood-donor pool and the recent implementation of testing of donated blood for HCV, the estimated incidence of acute infection among persons receiving transfusions is 5 to 10%. Alter *et al.*, in: Zuckerman, ed., *Viral*
25 *Hepatitis and Liver Disease*, Allen K. Liss, New York, 1988, pp. 537-542. Thus, of the approximately 3 million persons who receive transfusions in the United States each year, acute hepatitis C will develop in about 150,000. While many patients who contract hepatitis C will have subclinical or mild disease, approximately 50% will progress to a chronic disease state characterized by

fluctuating serum transaminase abnormalities and inflammatory lesions on liver biopsy. It is estimated that cirrhosis will develop in up to about 20% of this group. Koretz *et al.*, 1985, *Gastroenterology* **88**:1251-1254.

Interferons are known to affect a variety of cellular functions, including DNA replication and RNA and protein synthesis, in both normal and abnormal cells. Thus, cytotoxic effects of interferon are not restricted to tumor or virus infected cells but are also manifested in normal, healthy cells as well. As a result, undesirable side effects arise during interferon therapy, particularly when high doses are required. Administration of interferon can lead to bone marrow suppression resulting in reduced red blood cell, white blood cell and platelet counts. High doses of interferon commonly give rise to flu-like symptoms (e.g., fever, fatigue, headaches and chills), gastrointestinal disorders (e.g., anorexia, nausea and diarrhea), dizziness and coughing.

Interferon alpha-2b has been shown to be safe and effective when administered subcutaneously at a dose of 3×10^6 international units (IU) three times a week for 24 weeks for the treatment of chronic hepatitis C. Causse *et al.*, 1991, *Gastroenterology* **101**:497-502; Davis *et al.*, 1989, *New Eng. J. Med.* **321**:1501-1506; Marcellin *et al.*, 1991, *Hepatology*, **13**(3) :393-393. This amount and duration alleviates symptoms of hepatitis C and biochemical or histological evidence of ongoing inflammation of the liver in some patients but it also causes undesirable side effects, e.g., flu-like symptoms. Thus, thrice weekly injections place a burden on the patient and have a significant impact on the patient's quality of life.

Nieforth *et al.* (Clin. Pharmacol. Ther., 1996, **59**:636-646) has reported a comparison of the *in vivo* activity of Roferon®A and a polyethylene glycol-modified Roferon®A in healthy volunteers. The results, however, suggested that the conjugates could not be administered less than twice weekly and therefore offered little therapeutic advantage over the unmodified counterpart.

U.S. Patent Application Serial No. 08/742,305 discloses methods of administering polymer-cytokine conjugates to individuals susceptible to treatment with the cytokine, but does not disclose the method of this invention.

Polyethylene glycol modification of other proteins has also been reported. See Fuertges et al., 1990, Journal of Controlled Release 11:139-48, which reports PEG-modified asparaginase for treatment of acute lymphoblastic leukemia, PEG-adenosine deaminase (PEG-ADA) for use in ADA-deficient Severe Combined Immunodeficiency Syndrome, PEG-superoxide dismutase for reperfusion injury and PEG-uricase for treatment of hyperuricemia.

The undesirable side effects that accompany interferon alpha therapy and the burden of three weekly injections frequently limit the therapeutic usefulness of interferon alpha treatment regimes. Thus, a need exists to maintain or improve the therapeutic benefits of such therapy while reducing or eliminating the undesirable side effects.

15

Summary Of The Invention

The present invention fulfills this need by providing a method of treating conditions that are susceptible of treatment with interferon alpha, wherein efficacy is improved and undesirable side effects normally associated with such treatment are significantly diminished or eliminated entirely.

The present invention provides a method of treating a mammal afflicted with a viral infection that is susceptible to treatment with a interferon alpha comprising administering to the mammal an amount of a 12000 molecular weight polyethylene glycol conjugated interferon alpha (PEG₁₂₀₀₀-interferon alpha), which amount is effective to treat the viral infection while substantially reducing or eliminating adverse side effects normally associated with administration of interferon alpha.

25

The present invention also provides a method of treating chronic hepatitis C virus infection comprising administering to a mammalian host

infected with hepatitis C virus an amount of PEG₁₂₀₀₀-interferon alpha which is effective to treat said viral infection while simultaneously substantially reducing or eliminating side effects normally associated with administration of interferon alpha.

5

Detailed Description Of The Invention

The invention is directed to a method of treating conditions that are susceptible of treatment with interferon alpha. It has been unexpectedly discovered that administration of a 12000 molecular weight polyethylene glycol conjugated interferon alpha (hereinafter "PEG₁₂₀₀₀-IFN alpha") provides improved therapeutic benefits, while substantially reducing (or eliminating entirely) the undesirable side effects normally associated with conventionally practiced interferon alpha treatment regimes. In particular, it has surprisingly been found that administration once a week of a PEG₁₂₀₀₀-IFN alpha-2b conjugate to patients with chronic hepatitis C results in equal or increased efficacy while substantially reducing or eliminating the side effects normally associated with conventionally practiced interferon alpha treatment regimes.

Conventional interferon alpha therapy used for treating HCV in humans is 3 million international units three times a week ("3 MIU TIW"). This therapy normally leads to myelosuppression (reduction in white blood cells and neutrophil counts). Such doses or higher of interferon alpha commonly cause moderate to severe flu-like symptoms, gastrointestinal disorders, dizziness and coughing; each of these symptoms may require treatment with other therapies or force the patient to discontinue or reduce dosages of interferon alpha therapy.

Surprisingly, we have discovered that use of the preferred PEG₁₂₀₀₀-IFN alpha-2b conjugates in accordance with the present invention allows higher and less frequent doses with higher efficacy while simultaneously

and surprisingly substantially reducing or even eliminating the side effects and symptoms associated with conventional interferon alpha therapy.

The phrases "12,000 molecular weight polyethylene glycol conjugated interferon alpha" and "PEG₁₂₀₀₀-IFN alpha" as used herein mean
5 conjugates such as are prepared according to the methods of International Application No. WO 95/13090 and containing urethane linkages between the interferon alpha 2a or 2b amino groups and polyethylene glycol having an average molecular weight of 12000. The preferred polyethylene-glycol-interferon alpha conjugate is PEG₁₂₀₀₀-interferon alpha-2b.

10 The preferred PEG₁₂₀₀₀-interferon alpha-2b is prepared by attaching a PEG polymer to the epsilon amino group of a lysine residue in the IFN alpha-2b molecule. A single PEG₁₂₀₀₀ molecule is conjugated to free amino groups on an IFN alpha-2b molecule via a urethane linkage. This conjugate is characterized by the molecular weight of PEG₁₂₀₀₀ attached. The
15 PEG₁₂₀₀₀-IFN alpha conjugate is formulated as a lyophilized powder for injection. The objective of conjugation of IFN alpha with PEG is to improve the delivery of the protein by significantly prolonging its plasma half-life, and thereby provide protracted activity of IFN alpha.

The term "interferon" or "IFN" as used herein means the family of
20 highly homologous species-specific proteins that inhibit viral replication and cellular proliferation and modulate immune response. Human interferons are grouped into three classes based on their cellular origin and antigenicity: α -interferon (leukocytes), β -interferon (fibroblasts) and γ -interferon (B cells). Recombinant forms of each group have been developed and are commercially
25 available. Subtypes in each group are based on antigenic/structural characteristics. At least 24 interferon alphas (grouped into subtypes A through H) having distinct amino acid sequences have been identified by isolating and sequencing DNA encoding these peptides. The terms " α -interferon", "alpha interferon", "interferon alpha" and "human leukocyte interferon" are used

interchangeably in this application to describe members of this group. Both naturally occurring and recombinant α -interferons, including consensus interferon, may be used in the practice of the invention.

The purification of interferon alpha from human leukocytes isolated
5 from the buffy coat fraction of whole blood is described in U.S. Patent No. 4,503,035. Human leukocyte interferon prepared in this manner contains a mixture of human leukocyte interferons having different amino acid sequences. Purified natural human α -interferons and mixtures thereof which may be used in the practice of the invention include but are not limited to Sumiferon[®] interferon
10 alfa-n1 available from Sumitomo, Japan, Wellferon[®] interferon alfa-n1 (Ins) available from Glaxo-Wellcome Ltd., London, Great Britain, and Alferon[®] interferon alfa-n3 available from the Purdue Frederick Co., Norwalk, CT.

The advent of recombinant DNA technology applied to interferon production has permitted several human interferons to be successfully
15 synthesized, thereby enabling the large-scale fermentation, production, isolation, and purification of various interferons to homogeneity. Recombinantly produced interferon retains its *in vitro* and *in vivo* antiviral and immunomodulatory activities. It is also understood that the recombinant techniques could also include a glycosylation site for addition of a carbohydrate
20 moiety on the recombinantly-derived polypeptide.

The construction of recombinant DNA plasmids containing sequences encoding at least part of human leukocyte interferon and the expression in *E. coli* of a polypeptide having immunological or biological activity of human leukocyte interferon is disclosed in U.S. Patent No. 4,530,901
25 and European Patent No. EP 0 032 134. The construction of hybrid α -interferon genes containing combinations of different subtype sequences (e.g., A and D, A and B, A and F) is disclosed in U.S. Patent Nos. 4,414,150, 4,456,748 and 4,678,751. Typical suitable recombinant α -interferons which may be used in the practice of the invention include but are not limited to interferon alfa-2b such

as Intron[®] A available from Schering Corporation, Kenilworth, N.J., interferon alfa-2a such as Roferon[®] A available from Hoffmann-La Roche, Nutley, N.J.

U.S. Patent Nos. 4,695,623 and 4,897,471 disclose human leukocyte interferon polypeptides, referred to as consensus interferon, which have amino
5 acid sequences which include common or predominant amino acids found in each position among naturally-occurring interferon alpha subtype polypeptides.

Conditions that can be treated in accordance with the present invention are generally those that are susceptible to treatment with interferon alpha. For example, susceptible conditions include conditions which would
10 respond positively or favorably as these terms are known in the medical arts to interferon alpha-based therapy. For purposes of the invention, conditions that can be treated with interferon alpha therapy include those conditions in which treatment with an interferon alpha shows some efficacy, but which may not be treatable with interferon alpha because the negative side effects outweigh the
15 benefits of the treatment. For example, side effects accompanying alpha therapy have virtually ruled out treatment of Epstein Barr virus using interferon alpha. Practice of the invention results in substantially reduced or eliminated side effects as compared to conventional interferon alpha treatment.

Exemplary conditions which can be treated with interferon include
20 but are not limited to cell proliferation disorders, in particular cancer (e.g., hairy cell leukemia, Kaposi's sarcoma, chronic myelogenous leukemia, multiple myeloma, basal cell carcinoma and malignant melanoma, ovarian cancer, cutaneous T cell lymphoma), and viral infections. Without limitation, treatment with interferon may be used to treat conditions which would benefit from
25 inhibiting the replication of interferon-sensitive viruses. Viral infections which may be treated in accordance with the invention include hepatitis A, hepatitis B, hepatitis C, other non-A/non-B hepatitis, herpes virus, Epstein-Barr virus (EBV), cytomegalovirus (CMV), herpes simplex, human herpes virus type 6 (HHV⁶), papilloma, poxvirus, picornavirus, adenovirus, rhinovirus, human T lymphotropic

virus-type 1 and 2 (HTLV-1/-2), human rotavirus, rabies, retroviruses including human immunodeficiency virus (HIV), encephalitis and respiratory viral infections. The method of the invention can also be used to modify various immune responses.

5 Two variants of interferon alpha are currently approved in the United States and other countries for the treatment of hairy cell leukemia, venereal warts, Kaposi's Sarcoma, and chronic non-A/non-B hepatitis: interferon alfa-2b, marketed under the trade name INTRON® A (Schering Corporation, Kenilworth NJ) and interferon alfa-2a, marketed under the trade
10 name Roferon® A (Hoffmann-La Roche, Nutley, NJ). Since interferon alpha-2b, among all interferons, has the broadest approval throughout the world for treating chronic hepatitis C infection, it is most preferred for use in the treatment of chronic hepatitis C in accordance with practice of the invention.

A person suffering from chronic hepatitis C infection may exhibit
15 one or more of the following signs or symptoms: (a) elevated ALT, (b) positive test for anti-HCV antibodies, (c) presence of HCV as demonstrated by a positive test for HCV-RNA, (d) clinical stigmata of chronic liver disease, (e) hepatocellular damage. Such criteria may not only be used to diagnose hepatitis C, but can be used to evaluate a patient's response to drug treatment.

20 Elevated serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) are known to occur in uncontrolled hepatitis C, and a complete response to treatment is generally defined as the normalization of these serum enzymes, particularly ALT (Davis *et al.*, 1989, New Eng. J. Med. 321:1501-1506). ALT is an enzyme released when liver cells are destroyed
25 and is symptomatic of HCV infection. Interferon causes synthesis of the enzyme 2',5'-oligoadenylate synthetase (2'5'OAS), which in turn, results in the degradation of the viral mRNA. Houghlum, 1983, Clinical Pharmacology 2:20-28. Increases in serum levels of the 2'5'OAS coincide with decrease in ALT levels.

Histological examination of liver biopsy samples may be used as a second criteria for evaluation. See, e.g., Knodell *et al.*, 1981, *Hepatology* 1:431-435, whose Histological Activity Index (portal inflammation, piecemeal or bridging necrosis, lobular injury and fibrosis) provides a scoring method for disease activity.

In the practice of the invention, the preferred PEG₁₂₀₀₀-IFN alpha-2a or -2b conjugates may be administered to patients infected with the hepatitis C virus. Use of PEG₁₂₀₀₀-IFN alpha-2b is preferred.

Patients were selected for treatment from anti-HCV antibody patients with biopsy-documented chronic active hepatitis. Each patient was positive for antibody to hepatitis C virus (anti-HCV) by supplemental assay (Ortho or Abbot), had the presence of HCV RNA by PCR, and had previous liver biopsy with features of chronic hepatitis. Patients ranged from 18-68 years of age and had no previous interferon treatment for hepatitis C.

Three doses of PEG₁₂₀₀₀-IFN alpha-2b (0.5, 1.0, 1.5 µg/kg) administered once a week were found to have equal to or better antiviral activity than the interferon alpha control 3 MIU TIW (measured by loss of HCV-RNA(PCR)) at 4, 8 and 12 weeks of therapy. At the same time, side effects known to accompany interferon alpha treatment were significantly diminished.

The amount of the PEG₁₂₀₀₀-IFN alpha conjugate administered to treat any of the conditions described above is based on the IFN alpha activity of the polymeric conjugate. It is an amount that is sufficient to significantly affect a positive clinical response while maintaining diminished side effects. The amount of PEG₁₂₀₀₀-IFN alpha-2b which may be administered is in the range of at least about .25 µg/kg/week in single or divided doses. In more preferred embodiments, the amount administered is in the range of about 0.25 - 2.5 µg/kg/week, or 0.5 - 1.5 µg/kg/week in single or divided doses.

Administration of the described dosages may be every other day, but is preferably once or twice a week. Doses are administered over at least a 24 week period by injection.

Administration of the dose can be intravenous, subcutaneous, 5 intramuscular, or any other acceptable systemic method. Based on the judgment of the attending clinician, the amount of drug administered and the treatment regimen used will, of course, be dependent on the age, gender and medical history of the patient being treated, the neutrophil count (e.g. the severity of the neutropenia), the severity of the specific disease condition and 10 the tolerance of the patient to the treatment as evidenced by local toxicity and by systemic side-effects. Dosage amount and frequency may be determined during initial screenings of neutrophil count.

For any route of administration, divided or single doses may be used. For example, when a subcutaneous injection is used to deliver, for 15 example, 1.5 µg/kg of PEG₁₂₀₀₀-IFN alpha-2b over one week, two injections of 0.75 µg/kg at 0 and 72 hours may be administered.

In order to follow the course of HCV replication in subjects in response to drug treatment, HCV RNA may be measured in serum samples by, for example, a nested polymerase chain reaction assay that uses two sets of 20 primers derived from the NS3 and NS4 non-structural gene regions of the HCV genome. Farci *et al.*, 1991, *New Eng. J. Med.* 325:98-104. Ulrich *et al.*, 1990, *J. Clin. Invest.*, 86:1609-1614.

Antiviral activity may be measured by changes in HCV-RNA titre. HCV RNA data may be analyzed by comparing titres at the end of treatment with 25 a pre-treatment baseline measurement. Reduction in HCV RNA by week 4 provides evidence of antiviral activity of a compound. Kleter *et al.*, 1993, *Antimicrob. Agents Chemother.* 37(3):595-97; Orito *et al.*, 1995, *J. Medical Virology*, 46:109-115. Changes of at least two orders of magnitude ($\geq 2 \log$) is interpreted as evidence of antiviral activity.

Safety and tolerability may be determined by clinical evaluations and measure of white blood cell and neutrophil counts. This may be assessed through periodic monitoring of hematological parameters (white blood cell, neutrophil, platelet and red blood cell counts).

5 Other interferon conjugates can be prepared by coupling an interferon to a water-soluble polymer. A non-limiting list of such polymers include other polyalkylene oxide homopolymers such as polypropylene glycols, polyoxyethylenated polyols, copolymers thereof and block copolymers thereof. As an alternative to polyalkylene oxide-based polymers, effectively non-
10 antigenic materials such as dextran, polyvinyl pyrrolidones, polyacrylamides, polyvinyl alcohols, carbohydrate-based polymers and the like can be used. Such interferon-polymer conjugates are described in U.S. Patent No. 4,766,106, U.S. Patent No. 4,917,888, European Patent Application No. 0 236 987, European Patent Application No. 0 510 356 and International Application
15 Publication No. WO 95/13090.

Since the polymeric modification sufficiently reduces antigenic responses, the foreign interferon need not be completely autologous. Interferon used to prepare polymer conjugates may be prepared from a mammalian extract, such as human, ruminant or bovine interferon, or recombinantly
20 produced.

Various other extended- or sustained-release formulations can be prepared using conventional methods well known in the art.

Conventional pharmaceutical compositions comprising a therapeutically effective amount of PEG₁₂₀₀₀-IFN alpha together with
25 pharmaceutically acceptable carriers, adjuvants, diluents, preservatives and/or solubilizers may be used in the practice of the invention. Pharmaceutical compositions of interferon include diluents of various buffers (e.g., Tris-HCl, acetate, phosphate) having a range of pH and ionic strength, carriers (e.g., human serum albumin), solubilizers (e.g., tween, polysorbate), and

preservatives (e.g., thimerosal, benzyl alcohol). See, for example, U.S. Patent 4,496,537.

As described above, the course of the disease and its response to drug treatments may be followed by clinical examination and laboratory
5 findings. The effectiveness of the therapy of the invention is determined by the extent to which the previously described signs and symptoms of chronic hepatitis are alleviated and the extent to which the normal side effects of interferon (i.e., flu-like symptoms such as fever, headache, chills, myalgia, fatigue, etc. and central nervous system related symptoms such as depression,
10 paresthesia, impaired concentration, etc.) are eliminated or substantially reduced.

Many modifications and variations of this invention can be made without departing from its spirit and scope, as will be apparent to those skilled in the art. The specific embodiments described herein are offered by way of
15 example only, and the invention is to be limited only by the terms of the appended claims, along with the full scope of equivalents to which such claims are entitled.

CLAIMS

1. A method of treating a viral infection susceptible to
5 treatment with interferon alpha comprising administering an amount of PEG₁₂₀₀₀-IFN alpha to a mammal in need of such treatment, which amount is effective to treat said viral infection while reducing or eliminating adverse side effects normally associated with administration of interferon alpha.

10 2. A method of treating hepatitis C viral infections in mammals which comprises administering an amount of PEG₁₂₀₀₀-interferon alpha to mammals in need of such treating while substantially reducing or eliminating adverse side effects normally associated with administering interferon alpha.

15 3. The method of claim 2, wherein the PEG₁₂₀₀₀-IFN alpha is PEG₁₂₀₀₀-IFN alpha-2b.

4. The method of claim 2, wherein the PEG₁₂₀₀₀-IFN alpha is PEG₁₂₀₀₀-IFN alpha-2a.

20

5. The method of claim 2, wherein the amount of PEG₁₂₀₀₀-IFN alpha administered is at least about 0.25 µg/kg/week.

6. The method of claim 2, wherein the amount of PEG₁₂₀₀₀-
25 IFN alpha administered is about 0.25 µg/kg to about 1.5 µg/kg/week.

7. A method of treating hepatitis C viral infections in mammals which comprises administering at least about 0.25 µg/kg of PEG₁₂₀₀₀-interferon alpha-2b to a mammal in need of such treating.

8. The method of claim 7, wherein at least about 0.25 $\mu\text{g/kg}$ of PEG₁₂₀₀₀-interferon alpha-2b is administered per week.

5 9. The method of claim 7, wherein about 1.5 $\mu\text{g/kg}$ of PEG₁₂₀₀₀-interferon alpha-2b is administered per week.

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/US 98/07634

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 A61K47/48

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category ²	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X, P	WO 97 18832 A (USA) 29 May 1997 see page 14 - page 15; claims 13, 15, 19-23 see page 8, paragraph 1 ---	1-3, 5-9
Y, P	WO 97 16204 A (USA) 9 May 1997 see page 10, line 22 - page 11, line 7; claims 4, 5, 8, 9, 11-13 see page 8 ---	1-9
X	WO 95 13090 A (ENZON INC) 18 May 1995 cited in the application ---	1-9
Y	see claims 34, 42 see page 12, line 14-20 see claims 8, 12, 27-32; examples 2, 4-8, 10 ---	1-9
	-/--	



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

*** Special categories of cited documents:**

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

6 August 1998

Date of mailing of the international search report

21/08/1998

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Gonzalez Ramon, N

INTERNATIONAL SEARCH REPORT

Int. .onal Application No

PCT/US 98/07634

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y,P	EP 0 809 996 A (HOFFMANN LA ROCHE) 3 December 1997 see page 2, line 1-6 - line 20-24; claims 1,6,12-14; example 1 ----	1,2,4-6
A	EP 0 593 868 A (HOFFMANN LA ROCHE) 27 April 1994 see claims 9,19,21,22,24; examples 1,9 ----	1-9
X	WO 96 11953 A (AMGEN INC) 25 April 1996 see page 24, line 20 - page 25, line 10; claims 21,24,26,27,34-36; example 3 see page 21, line 1-10 ----	1-9
A	COTTRILL C.P. ET AL: "Cancer and HIV infection" CLINICAL ONCOLOGY, 1997, 9/6 (365-380), XP002073551 United Kingdom see page 369 -----	1-9

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 98/07634

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 1-9
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claim(s) 1-9
is(are) directed to a method of treatment of the human/animal
body, the search has been carried out and based on the alleged
effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such
an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 98/07634

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9718832 A	29-05-1997	US 5738846 A	14-04-1998
		AU 7600496 A	11-06-1997
WO 9716204 A	09-05-1997	AU 7473096 A	22-05-1997
WO 9513090 A	18-05-1995	AU 691225 B	14-05-1998
		AU 1179895 A	29-05-1995
		EP 0730470 A	11-09-1996
		HU 75533 A	28-05-1997
		JP 9506087 T	17-06-1997
		US 5711944 A	27-01-1998
EP 0809996 A	03-12-1997	AU 2372397 A	04-12-1997
		BG 101540 A	27-02-1998
		CA 2203480 A	30-11-1997
		CN 1167777 A	17-12-1997
		CZ 9701679 A	17-12-1997
		DE 809996 T	09-04-1998
		ES 2110386 T	16-02-1998
		HR 970298 A	30-04-1998
		HU 9700959 A	02-03-1998
		JP 10067800 A	10-03-1998
		NO 972480 A	01-12-1997
		PL 320251 A	08-12-1997
		SK 67397 A	10-12-1997
EP 0593868 A	27-04-1994	US 5382657 A	17-01-1995
		AT 165102 T	15-05-1998
		AU 668742 B	16-05-1996
		AU 4478093 A	03-03-1994
		BG 98067 A	15-11-1994
		BR 9303469 A	22-03-1994
		CA 2103829 A	27-02-1994
		CN 1088936 A	06-07-1994
		CN 1173500 A	18-02-1998
		CZ 9301693 A	13-04-1994
		DE 69317979 D	20-05-1998
		FI 933740 A	27-02-1994
		HR 931094 A	30-06-1997
		HU 67013 A	30-01-1995

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 98/07634

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0593868 A		JP 6192300 A	12-07-1994
		LT 3174 B	27-02-1995
		LV 10907 A	20-12-1995
		LV 10907 B	20-04-1996
		MW 7693 A	08-06-1994
		MX 9305146 A	31-03-1994
		NZ 248452 A	21-12-1995
		NZ 264872 A	26-01-1996
		OA 9850 A	15-08-1994
		PL 300194 A	05-04-1994
		SI 9300423 A	31-03-1994
		SK 89893 A	06-04-1994
		ZA 9306098 A	01-03-1994
		ZW 11193 A	23-03-1994
WO 9611953 A	25-04-1996	AU 1841995 A	06-05-1996
		CA 2178752 A	25-04-1996
		CN 1139932 A	08-01-1997
		EP 0733067 A	25-09-1996
		EP 0822199 A	04-02-1998
		JP 9025298 A	28-01-1997
		JP 9506116 T	17-06-1997
		NZ 281469 A	24-04-1997